Abstract

Objective To investigate the diagnostic value of human epididymis protein (HE4) and carbohydrate antigen-125 (CA125) in ovarian cancer. Methods From January 2009 to August 2010, 59 women with pelvic mass were included into this study. They were divided into two groups according to pathological examination after operation, ovarian cancer group (n=29) and pelvic benign diseases groups (n=30). Meanwhile, another 37 healthy women who had the physical examination during the same period were recruited into control group. The study protocol was approved by the Ethical Review Board of Investigation in Human Being of West China Second University Hospital, Sichuan University. Informed consent was obtained from all participants. The single and combined detection of HE4 and CA125 levels in the serum from three groups were quantitatively determined by enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay (CLIA). At last, the area under curve (AUC) of the total results were evaluated by receiver operating characteristic curve (ROC). Results Serum HE4 and CA125 levels in ovarian cancer group were significantly higher than those in other two groups with statistically significant difference (P 0.05). Reference to benign disease group(AUC=1), the correspondence AUC by ROC of HE4, CA125 and the both indexes were 0.924, 0.793 and 0.931, respectively, and the cut off value of HE4 and CA125 in clinical diagnosis was 73.5 pmol/L and 35 IU/mL, respectively. Conclusions Combined detection of HE4 and CA125 could improve the sensitivity and efficiency in the diagnosis of early ovarian cancer. Key words: receiver operating characteristic curve; human epididymal protein 4; carbohydrate antigen 125; ovarian cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call